Alios BioPharma is a biotechnology company located in South San Francisco, California, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an innovative team of highly experienced scientists and clinical researchers who are developing direct acting antiviral agents against several human viral pathogens of public health importance including, hepatotropic viruses, respiratory viruses and other chronic, acute and emerging viral diseases. Additionally, Alios is developing molecular activators of an interferon induced, broad spectrum antiviral innate immune pathway called RNase-L.  The overall goal for the Alios therapeutic platform is to maximize patient benefits in areas of high unmet medical need through optimization of potency, safety and tolerability.

Alios has a staff of 30 full time employees, of which 24 are scientists, working in a 20,000 square foot facility. Alios management has discovered or led the development of numerous compounds that have reached the clinic for the treatment of chronic hepatitis C. We are funded by an experienced group of Venture Capital backers with extensive industry experience including: Novo A/S, Novartis Ventures, Roche Ventures, and SR-One (GlaxoSmithKline ventures).